Cover Image
市場調查報告書

Adefovir的中國市場分析

Investigation Report on China Adefovir Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334092
出版日期 內容資訊 英文 35 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Adefovir的中國市場分析 Investigation Report on China Adefovir Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 35 Pages
簡介

中國國內目前B型肝炎表面抗原(HBsAg:HBs抗原)造成的死亡人數比例雖然低,但由於患者數量大,B型肝炎患者數為9000萬人,慢性B型肝炎患者數為2000萬人,兩方都到相當高的人數。Adefovir是CHB治療藥核苷酸類似體的一種,中國目前市場規模正在急速成長。2005年約1000萬人民幣的銷售額,約以60%程度的年平均成長率(CAGR)擴大,到2014年達到了4億人民幣。

本報告提供中國的Adefovir的市場相關分析,提供您整體市場規模趨勢(過去5年份)和國內價格趨勢,各企業·給藥型態別的市場佔有率,主要製造商簡介,未來性的市場趨勢預測(今後5年份)等調查評估。

第1章 Adefovir的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Adefovir市場概況

  • 中國國內的Adefovir的專利申請·認證情形
  • 主要製造商
  • 市場規模

第3章 Adefovir銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Adefovir市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (以銷售額為準)
  • 市場佔有率 (以銷售量為準)

第5章 中國的Adefovir市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (以銷售額為準)
  • 各劑型的市場佔有率 (以銷售量為準)

第6章 Adefovir的醫院用標準價格

  • YSY (Shanghai) Pharmaceutical Co., Ltd
  • TIPR Pharmaceutical Responsible Co., Ltd (商標名:Daiding)
  • Qilu Pharmaceutical Co., Ltd (商標名:Yilaifen)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd (商標名:Mingzheng)
  • United Laboratories (商標名:Adixian)
  • Fujian Cosunter Pharmaceutical Co., Ltd (商標名:Aganding)
  • GlaxoSmithKline (Tianjin) Co., Ltd (商標名:Hepsera)

第7章 中國國內的Adefovir的主要製造商 (過去5年份)

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • TIPR Pharmaceutical Responsible Co., Ltd
  • United Laboratories
  • Fujian Cosunter Pharmaceutical Co., Ltd
  • GlaxoSmithKline (Tianjin) Co., Ltd

第8章 中國的Adefovir市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1507253

In Mar. 2015, WHO issued Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, indicating that 2 billion people around the world had or are having HBV infection and that about 240 million people are infected with chronic hepatitis B virus (HBV), among which 0.65 million die of hepatitis B-related diseases. Hepatitis B surface antigen (HBsAg ) rate among people aged below 60 has fallen from 9.75% a decade ago to 7.18% now. However, since China has a large population base, the number of people infected with chronic HBV is calculated to be over 90 million and the number of chronic hepatitis B (CHB) patients is 20 million. Hence, the severe status of diagnosis and treatment of CHB. So far, chronic and viral hepatitis B has become one of the major threats to human health and CHB has already become the ninth leading cause of death.

Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.

In 2002, GlaxoSmithKline (GSK) acquired the franchise rights to market adefovir dipivoxil, the anti-hepatitis B drug of Gilead Sciences, Inc. in mainland China, Japan, Korea and Taiwan under the trade name of Hepsera. In 2013, the global sales value of Hepsera was down by 23.81%. In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.

Adefovir develops fast after entering China, annual sales value rising from about CNY 10 million in 2005 to CNY 400 million in 2013 and CAGR reaching nearly 60% during the period of 2005-2014. GlaxoSmithKline (Tianjin) Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline (Tianjin) Co., Ltd had the largest market share of about 43% for sales value in 2014.

With the large amounts of hepatitis B patients in China, the market size of adefovir is expected to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of adefovir in China
  • competitive landscape of adefovir in Chinese market
  • price of adefovir made by different enterprises in China
  • market outlook of adefovir in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-hepatitis drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Adefovir

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Adefovir in China

  • 2.1. Patent and Approval Status of Adefovir in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Adefovir in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Adefovir in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Adefovir in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Adefovir in Chinese Hospitals in 2014

  • 6.1. YSY (Shanghai) Pharmaceutical Co., Ltd
  • 6.2. TIPR Pharmaceutical Responsible Co., Ltd (Trade Name: Daiding)
  • 6.3. Qilu Pharmaceutical Co., Ltd (Trade Name: Yilaifen)
  • 6.4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Mingzheng)
  • 6.5. United Laboratories (Trade Name: Adixian)
  • 6.6. Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: Aganding)
  • 6.7. GlaxoSmithKline (Tianjin) Co., Ltd (Trade Name: Hepsera)

7. Major Manufacturers of Adefovir in Chinese Market, 2010-2014

  • 7.1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.2. TIPR Pharmaceutical Responsible Co., Ltd
  • 7.3. United Laboratories
  • 7.4. Fujian Cosunter Pharmaceutical Co., Ltd
  • 7.5. GlaxoSmithKline (Tianjin) Co., Ltd

8. Market Outlook of Adefovir in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Adefovir in China
  • Chart Approval Information of Adefovir in China
  • Chart Sales Status of Adefovir in China
  • Chart Sales Value of Adefovir in China, 2010-2014
  • Chart Sales Value of Adefovir in Some Regions in China, 2010-2014
  • Chart Sales Volume of Adefovir in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Adefovir for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Made by GlaxoSmithKline (Tianjin)in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Made by TIPR in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Capsules in China, 2010-2014
  • Chart Price of Adefovir Made by YSY (Shanghai) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by TIPR Pharmaceutical Responsible Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by United Laboratories in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by GlaxoSmithKline (Tianjin) Co., Ltd in Some Chinese Cities in 2014
Back to Top